Earnings Call Summary | NovaBay Pharmaceuticals(NBY.US) Q1 2024 Earnings Conference
The following is a summary of the NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript:Financial Performance:NovaBay Pharmaceuticals reported Q1 2024 total sales of $2.6 million, a 12%
NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, Vs. Street Est of $3.28M
04:33 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M
NovaBay Pharmaceuticals | 10-Q: Quarterly report
Express News | NovaBay Pharmaceuticals Q1 EPS USD -0.15
NovaBay 1Q Loss/Shr 15c >NBY
NovaBay 1Q Loss/Shr 15c >NBY
DJ NYSE American Most Active Issues
VOLUME ACTIVES COMPANY SYMBOL VOLUME LAST CHANGE PERCENT ------- ------ ------ ---- ------ ------- Tel
NovaBay Pharmaceuticals Announces Record Ordered Product Sales Of Avenova-Branded Products Through Amazon For April 2024 Increased By More Than 20% Compared With April 2023
Ordered product sales of Avenova-branded products on Amazon.com set back-to-back records in March and April 2024Enhanced marketing program provides potential for additional growth in the U.S. dry eye
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersFibroGen (NASDAQ:FGEN) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yes
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community
Express News | NovaBay Pharmaceuticals Notified By NYSE American Of Stockholder Equity Compliance Issue
NovaBay Pharmaceuticals Receives NYSE Notice for Compliance
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity.
Express News | NovaBay Pharmaceuticals: on April 18, Got Notice From NYSE American Stating Co Is Below Compliance With NYSE American Continued Listing Standards
Express News | NovaBay Pharmaceuticals Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Preliminary Q1 Net Revenue Results
Express News | NovaBay Pharmaceuticals Reports Preliminary Q1 FY24 Net Revenue For Its Eyecare And Wound Care Business Of $2.6M, Up 13% YoY
Express News | NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Express News | NovaBay Pharmaceuticals Inc : Ascendiant Capital Markets Cuts Target Price to $2 From $3.5
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript
Earnings Call Summary | NovaBay Pharmaceuticals(NBY.US) Q4 2023 Earnings Conference
The following is a summary of the NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript:Financial Performance:NovaBay reported a total Q4 2023 sales net of $3.7 million, marking a 2% in
No Data